Sponsored member content
Diagnosing respiratory disease during telehealth consults can be challenging as clinicians can’t use their standard tools, typically a stethoscope, chest x-ray or spirometer, for evaluating acute respiratory symptoms.
Designed for telehealth, ResAppDx is an app-based, remote test for patients who present with respiratory symptoms. Validated in large Australian clinical studies, ResAppDx uses AI algorithms to listen for unique features in cough sounds to indicate the presence of lower respiratory tract disease, pneumonia, asthma/reactive airway disease exacerbations, COPD exacerbations, bronchiolitis and croup.
For example, if a patient presents with a cough and fever during a telehealth consultation, without a stethoscope, it is difficult to identify lung sounds typically associated with pneumonia. By analysing the patient’s cough, ResAppDx is able to identify these sounds and assist in making the correct diagnosis, increasing confidence in treatment decisions. ResAppDx has now been approved by the TGA for ARTG listing as a class IIa medical device.
When requested by their clinician, the patient simply downloads the app on their own phone to capture five cough sounds and the test result is instantly sent to their doctor. No additional equipment or physical contact is necessary, reducing the spread of infection.
If you are a clinician, learn more about ResAppDx and sign up for a free trial
ResAppDx will be available on Android soon. Only indicated for use on patients aged 29 days and older. The result of the test should not be used as a sole diagnosis. The result should be used as part of an overall clinical assessment of the patient. Please refer to the Instructions for Use for information on interpreting the results and the clinical performance of ResAppDx. ResAppDx is listed on the Australian Register of Therapeutic Goods (ARTG). Always read the Instructions for Use. ResApp Health Ltd, Level 12, 100 Creek Street, Brisbane Qld 4000.